Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Glucagon.

To understand the physiology of this effect, indices of α- and β-cell function were measured in a subpopulation of Chinese patients following a noodle mixed-meal tolerance test.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

Also glycemic variables, HbA1c, FPG, and PPG (AUC0-180), and homeostasis model assessment (HOMA) 2β were measured.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The end points for β- and α-cell function were change from baseline in C-peptide, insulin, and glucagon areas under the curve from 0 to 180 min (AUC0-180), insulinogenic index, and insulin sensitivity from Matsuda index after a mixed meal.

What Was Measured

PubMed files the paper under topics including Adamantane, Asian People, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Dipeptides and Dipeptidyl-Peptidase IV Inhibitors.

The authors tagged it with the keywords China, DPP-4 inhibitors, Mixed-meal tolerance test, Saxagliptin and Type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized and double-blind study of Glucagon.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the Glucagon compound page, all human trials.